Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00167310
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Active, not recruiting Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
Conditions: Schizophrenia;   Schizoaffective Disorder;   Major Depression;   Bipolar Disorder;   Coronary Artery Disease
Interventions: Drug: Eicosapentaenoic acid (omega-3 fatty acid);   Drug: Placebo

Indicates status has not been verified in more than two years